Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Wuzhong Pharmaceutical is a prominent Chinese pharmaceutical company and a core subsidiary of the Shanghai-listed Jiangsu Wuzhong Industrial Co., Ltd. Headquartered in Suzhou, the company integrates R&D, manufacturing, and marketing of a diverse portfolio including anti-infectives, cardiovascular drugs, and gastrointestinal treatments. Recently, the company has undergone a significant strategic transformation to enter the medical aesthetics sector, highlighted by the 2024 China approval of AestheFill, a high-end PDLLA-based injectable filler. Wuzhong Pharma operates multiple GMP-certified production bases and is actively developing a pipeline of recombinant collagen and other innovative aesthetic solutions. The company aims to leverage its established pharmaceutical manufacturing expertise to become a leader in the pharmaceutical and aesthetics dual-core industry in China.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiangsu Wuzhong Pharmaceutical.